Skip to main content

Ulcer

1
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Esteve
EsteveSpain - Barcelona
1 program
1
Calcium DobesilatePhase 31 trial
Active Trials
NCT00979836Suspended230
Integra LifeSciences
Integra LifeSciencesAustralia - Clayton
1 program
Active Leptospermum HoneyN/A1 trial
Active Trials
NCT02482948Terminated10Est. Mar 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
EsteveCalcium Dobesilate
Integra LifeSciencesActive Leptospermum Honey

Clinical Trials (2)

Total enrollment: 240 patients across 2 trials

NCT00979836EsteveCalcium Dobesilate

Calcium Dobesilate for Chronic Venous Wounds

Start: Apr 2008230 patients
Phase 3Suspended
NCT02482948Integra LifeSciencesActive Leptospermum Honey

MEDIHONEY® Gel Versus Collagenase for Wound Debridement

Start: Jun 2015Est. completion: Mar 201710 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.